MischleyLK.Lithium deficiency in Parkinson's disease. Master's thesis, University of Washington, 2012.
3.
van EijkRPA, JonesAR, SprovieroW, et al.Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials. Neurology, 2017; 89:1915–1922.
4.
KessingLV, GerdsTA, KnudsenNN, et al.Association of lithium in drinking water with the incidence of dementia. JAMA Psychiatry, 2017; 74:1005–1010.
5.
CiliaR, LagunaJ, CassaniE, et al.Mucuna pruriens in Parkinson disease: A double-blind, randomized, controlled, crossover study. Neurology, 2017; 89:432–438.
6.
CeredaE, CiliaR, CanesiM, et al.Efficacy of rasagiline and selegiline in Parkinson's disease: A head-to-head 3-year retrospective case-control study. J Neurol, 2017; 264:1254–1263.
7.
Alves Da RochaP, McClellandJ, MorrisME. Complementary physical therapies for movement disorders in Parkinson's disease: A systematic review. Eur J Phys Rehabil Med, 2015; 51:693–704.
8.
WeintraubD, ClaassenDO. Impulse control and related disorders in Parkinson's disease. Int Rev Neurobiol, 2017; 133:679–717.
9.
PetersonE, ForlanoR. Partial dopamine agonist-induced pathological gambling and impulse-control deficit on low-dose aripiprazole. Australas Psychiatry, 2017; 25:614–616.
10.
HorganJ.Profile: Linus C. Pauling–Stubbornly ahead of his time. Sci Am, 1993; 266:36–40.
11.
StolzenbergE, BerryD, Yang, et al.A role for neuronal alpha-synuclein in gastrointestinal immunity. J Innate Immun, 2017; 9:456–463.
12.
LionnetA, Leclair-VisonneauL, NeunlistM, et al.Does Parkinson's disease start in the gut?. Acta Neuropathol, 2018; 135:1–12.
13.
AbbasMM, XuZ, TanLCS. Epidemiology of Parkinson's disease—East versus west. Mov Disord Clin Pract, 2017; 5:14–28.
14.
GBD 2016 Parkinson's disease collaborators. Global, regional, and national burden of Parkinson's disease, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol, 2018; 17:939–953.
15.
RascolO.“Disease-modification” trials in Parkinson disease: Target populations, endpoints and study design. Neurology, 2009; 72:S51–S58.
16.
ZhuZG, SunMX, ZhangWL, et al.The efficacy and safety of coenzyme Q10 in Parkinson's disease: A meta-analysis of randomized controlled trials. Neurol Sci, 2017; 38:215–224.
17.
Attia, AhmedH, GadelkarimM, et al.Meta-analysis of creatine for neuroprotection against Parkinson's disease. CNS Neurol Disord Drug Targets, 2017; 16:169–175.
18.
MischleyLK, LauRC, BennettRD. Role of diet and nutritional supplements in Parkinson's disease progression. Oxid Med Cell Longev, 2017; 2017:640527–8.
19.
CostantiniA, FancelluR. An open-label pilot study with high-dose thiamine in Parkinson's disease. Neural Regen Res, 2016; 11:406–407.
20.
PerryTL, GodinDV, HansenS.Parkinson's disease: A disorder due to nigral glutathione deficiency?. Neurosci Lett, 1982; 33:305–310.
MischleyLK, LeverenzJB, LauRC, et al.A randomized, double-blind Phase I/IIa study of intranasal glutathione in Parkinson's disease. Mov Disord, 2015; 30:1696–1701.
23.
MischleyLK, LauRC, ShanklandEG, et al.Phase IIb study of intranasal glutathione in Parkinson's disease. J Parkinsons Dis, 2017; 7:289–299.
24.
MischleyLK, ConleyKE, ShanklandEG, et al.Central nervous system uptake of intranasal glutathione in Parkinson's disease. NPJ Parkinsons Dis, 2016; 2:1600–2.
25.
LiYH, HeQ, YuJZ, et al.Lipoic acid protects dopaminergic neurons in LPS-induced Parkinson's disease model. Metab Brain Dis, 2015; 30:1217–1226.
26.
RajaballyYA, MarteyJ. Levodopa, vitamins, ageing and the neuropathy of Parkinson's disease. J Neurol, 2013; 260:2844–2848.
27.
Martí MassóJF, UrtasunM.Citicoline in the treatment of Parkinson's disease. Clin Ther, 1991; 13:239–242.
28.
EberhardtR, BirbamerG, GerstenbrandF, et al.Citicoline in the treatment of Parkinson's disease. Clin Ther, 1990; 12:489–495.
29.
CubellsJM, HernandoC. Clinical trial on the use of cytidine diphosphate choline in Parkinson's disease. Clin Ther, 1988; 10:664–671.
